The patent covers both the effects of PA when ingested alone, as well as in combination with nutritional ingredients like creatine.
Chemi Nutra (White Bear Lake, MN) has filed a novel patent linking the oral use of phosphatidic acid (PA) with increased muscle mass and strength in mammals. The patent covers both the effects of PA when ingested alone, as well as in combination with nutritional ingredients like creatine.
According to the company, research has shown that PA plays a key role in activating mTOR (mammalian target of rapamycin) signaling. mTOR signaling is said to be key in skeletal muscle growth and strength gain. PA acts as a lipid messenger to signal the mTOR mechanism, and an elevation in PA concentration has been shown to be sufficient for activating mTOR signaling.
Chemi Nutra adds that PA has been shown to exhibit noticeable effects on strength development, “especially when adequate amounts of protein, administered within the anabolic window, were provided to exercising individuals.”
The company says that the filing of the novel patent (US Patent Application Number 13/373,649) could have major implications in the areas of sports nutrition, healthy aging and sarcopenia (age-related muscle loss), and in cachectic (bedridden) patients.
In conjunction with the patent filing, Chemi Nutra’s president, Scott Hagerman, says that company has concurrently developed a new ingredient called Mediator 50P Phosphatidic Acid. The ingredient will be marketed early this year.
“We are very, very excited about this new specialty ingredient compound, and we already have a number of interested companies who are quite eager to use it in their new product formulations,” he said via press release.